xGenetic analysis systems developer Agena Bioscience has launched targeted research panels UltraSEEK and iPLEX HS, for the detection of somatic mutations from lung and colon cancers.
The UltraSEEK lung and colon panels can detect mutations as low as 0.1% minor allele frequency (MAF) from circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), while iPLEX HS can detect mutations as low as 1% MAF from solid tumour tissue.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The panels are designed to complement the firm's MassARRAY system which detects mutations as low as 0.1% MAF from minimal input DNA.
The low-limit detection capacity of the panels facilitates mutation profiling of ctDNA and CTCs from plasma, as well as solid tumour tissue.
The multiplexed panels can work with DNA extracted from a single, 10mL blood draw and target mutations of known significance in BRAF, EGFR, ERBB2, KRAS, NRAS and PIK3CA genes.
In collaboration with the Medical Foundation, a clinical research study was conducted using the iPLEX HS lung panel, SCLC solid tumour samples and a limit of detection of 1% MAF.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe results showed about 10% increase in the number of clinically significant mutations detected compared to other methods with a 5-10% MAF.
The results were found to be consistent in case of colorectal adenocarcinoma samples, where an increase of approximately 6% in the number of mutations detected, was demonstrated.
The panels provide cost-effective mutational profiling across various sample types such as liquid biopsies, and are suitable for laboratories translating discoveries from clinical research to higher throughput testing.
